Emerging infectious diseases · 2013 · 114 citations · 31 references
Public HealthInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyClinical MedicineTuberculosis ControlAntiretroviral TherapyTuberculosis CareTuberculosis EpidemiologyExtensively Drug-resistant Tuberculosis TreatmentHiv-tuberculosis Treatment Co-managementHuman Immunodeficiency Virus-associated TuberculosisSputum MicrobiologySputum Smear ConversionTreatment Outcome AnalysisTreatment Outcome MeasurementTreatment Outcome Monitoring
High mortality rates have been reported for patients co-infected with extensively drug-resistant tuberculosis (XDR-TB) and HIV, but treatment outcomes have not been reported. We report treatment outcomes for adult XDR TB patients in KwaZulu-Natal Province, South Africa. Initial data were obtained retrospectively, and outcomes were obtained prospectively during 24 months of treatment. A total of 114 XDR TB patients were treated (median 6 drugs, range 3-9 drugs); 82 (73%) were HIV positive and 50 (61%) were receiving antiretroviral therapy. After receiving treatment for 24 months, 48 (42%) of 114 patients died, 25 (22%) were cured or successfully completed treatment, 19 (17%) withdrew from the study, and 22 (19%) showed treatment failure. A higher number of deaths occurred among HIV-positive patients not receiving antiretroviral therapy and among patients who did not show sputum culture conversion. Culture conversion was a major predictor of survival but was poorly predictive (51%) of successful treatment outcome.
31
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch et al. · New England Journal of Medicine · 2009 · 839 citations · Full text
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler, Vija Skripconoka, Epifanio Sànchez-Garavito et al. · New England Journal of Medicine · 2012 · 737 citations · Full text